Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/10288
A Multinational, Preregistered Cohort Study of beta-Lactam/beta-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae
Identifiers
DOI: 10.1128/AAC.00365-16
ISSN: 0066-4804
eISSN: 1098-6596
WOS ID: 000378094400034
Scopus EID: 2-s2.0-84977072761
PMID: 27139473
Embase PUI: L611027865
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Gutierrez-Gutierrez, Belen; Perez-Galera, Salvador; Salamanca, Elena; de Cueto, Marina; Calbo, Esther; Almirante, Benito; Viale, Pierluigi; Oliver, Antonio

Publication date
2016-07Document type
research articleCitation
Gutierrez-Gutierrez Belen, Perez-Galera Salvador, Salamanca Elena, De Cueto Marina, Calbo Esther, Almirante Benito, et al. A Multinational, Preregistered Cohort Study of beta-Lactam/beta-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016 Jul;60(7):4159-4169.Abstract
The spread of extended-spectrum-beta-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems need to be investigated. We investigated whether beta-lactam/beta-lactamase inhibitor (BLBLI) combinations are as effective as carbapenems in the treatment of bloodstream infections (BSI) due to ESBL-E. A multinational, retrospective cohort study was performed. Patients with monomicrobial BSI due to ESBL-E were studied; specific criteria were applied for inclusion of patients in the empirical-therapy (ET) cohort (ETC; 365 patients), targeted-therapy (TT) cohort (TTC; 601 patients), and global cohort (GC; 627 patients). The main outcome variables were cure/improvement rate at day 14 and all-cause 30-day mortality. Multivariate analysis, propensity scores (PS), and sensitivity analyses were used to control for confounding. The cure/improvement rates with BLBLIs and carbapenems were 80.0% and 78.9% in the ETC and 90.2% and 85.5% in the TTC, respectively. The 30-day mortality rates were 17.6% and 20% in the ETC and 9.8% and 13.9% in the TTC, respectively. The adjusted odds ratio (OR) (95% confidence interval [CI]) values for cure/improvement rate with ET with BLBLIs were 1.37 (0.69 to 2.76); for TT, they were 1.61 (0.58 to 4.86). Regarding 30-day mortality, the adjusted OR (95% CI) values were 0.55 (0.25 to 1.18) for ET and 0.59 (0.19 to 1.71) for TT. The results were consistent in all subgroups studied, in a stratified analysis according to quartiles of PS, in PS-matched cases, and in the GC. BLBLIs, if active in vitro, appear to be as effective as carbapenems for ET and TT of BSI due to ESLB-E regardless of the source and specific species. These data may help to avoid the overuse of carbapenems. (This study has been registered at ClinicalTrials.gov under registration no. NCT01764490.)
Publisher version
https://dx.doi.org/10.1128/AAC.00365-16MeSH
BacteremiaAged
Kaplan-Meier Estimate
Carbapenems
Anti-Bacterial Agents
Humans
Enterobacteriaceae
Middle Aged
Male
Multivariate Analysis
Female
Odds Ratio
beta-Lactamases
beta-Lactamase Inhibitors
beta-Lactams
Retrospective Studies
DeCS
Oportunidad RelativaFemenino
Análisis Multivariante
Masculino
Enterobacteriaceae
Humanos
Persona de Mediana Edad
Estimación de Kaplan-Meier
Anciano
Inhibidores de beta-Lactamasas
Bacteriemia
beta-Lactamas
Estudios Retrospectivos
Antibacterianos
beta-Lactamasas
Carbapenémicos
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica